Most of the debate around biotech right now is in the wrong place.

People are arguing about rates, about whether the rally has run too far, about FDA uncertainty, about China trade friction. All of that is real. None of it is the main event. The main event is a balance sheet problem that the largest pharmaceutical companies on earth cannot solve without writing very large checks to very small biotech companies. That problem does not get better if rates stay high. It does not get better if equity markets wobble. It gets worse every quarter, on a schedule that was set years ago and has not changed.

The number is $300 billion. That is how much pharmaceutical revenue sits at risk from patent expirations by 2030, and it is not a projection or a range. It is a calendar.

Merck’s Keytruda did $31.7 billion in sales in 2025. U.S. patent exposure hits in 2028. Bristol Myers Squibb has roughly $38 billion in at-risk revenue across its portfolio right now. Eight of the thirteen largest pharma companies, accounting for 55% of global pharma market value, could see 30% or more of their top line threatened before the decade is out. There is no internal R&D program that fixes a gap that large in that timeframe. The only real response is acquisition, and the capacity to execute it is sitting there ready: an estimated $1.3 trillion in combined deal capacity across the top 25 companies. The $133 billion M&A surge in 2025, which ran 133% above the prior year, barely moved that number.

So the first half of 2026 happened the way it did. $134 billion in biopharma deal value. Forty-eight transactions tracked through June. Q1 alone crossed $65 billion, the strongest single quarter since 2020. Sixteen deals over $1 billion announced in those first three months. Seven deals worth $29 billion combined closed in a twelve-day stretch in late March.

That last one is worth slowing down on. Twelve days.

Merck paid $6.7 billion for Terns Pharmaceuticals and TERN-701, its oral chronic myeloid leukemia drug candidate. Eli Lilly put $6.3 billion on the table for Centessa Pharmaceuticals upfront, with up to $1.5 billion more in milestones, targeting its sleep disorder pipeline. AbbVie acquired Apogee for $10.9 billion to expand in next-generation immunology. GSK bought Nuvalent for $10.6 billion. Merck KGaA took Bio-Techne at an $11.3 billion enterprise value. Lilly separately made a platform move into in vivo CAR-T through Kelonia. J&J stepped into degrader-antibody conjugates via Firefly Bio. The therapeutic categories touched in that run: oncology, immunology, sleep medicine, cell therapy, antibody engineering. That is not a focused acquisition campaign. That is every major pharma buyer moving at once across every category they care about.

Here is where it gets interesting at the index level. The XBI, which is equal-weight across its holdings, has returned roughly 81% over the trailing twelve months through early July 2026. The IBB, cap-weighted and dominated by Amgen, Gilead, Regeneron, has lagged that number by a meaningful margin over the same window. The reason for that gap is structural, not incidental. In an equal-weight index, a $400 million clinical-stage oncology company moves the needle the same way Regeneron does. When acquisitions are coming in at 50% to 80% premiums on exactly those smaller names, XBI captures it. IBB largely does not. That spread is information.

The AI layer inside this cycle is still being underpriced by the market. Not in a hype sense. In a very specific, practical sense. PwC’s midyear 2026 pharma outlook noted that acquirers are now explicitly modeling AI infrastructure as part of deal underwriting, looking at how a target company’s AI capabilities can compress discovery timelines, cut trial costs, and accelerate regulatory submissions. Advanced models are predicting protein structures and biological interactions at a speed that reduces early-stage R&D spend meaningfully. A Phase 3 failure is still a Phase 3 failure, that has not changed. But a smaller biotech with genuine AI-driven discovery infrastructure carries more defensible platform value today than the same company would have in 2021, and pharma buyers are pricing that in. Which means the market probably is not, yet.

The risks are real and worth being direct about. FDA consistency is a genuine operational problem. Leadership turnover inside the Center for Drug Evaluation and Research has produced approval signals that have been, at times, difficult to read. Surprise rejections have hit names where the underlying science was not the issue. That kind of unpredictability is costly in a sector where the entire valuation model runs on regulatory timing.

The BIOSECURE Act, signed into law in December 2025 as part of the FY2026 defense authorization bill, has added friction to deal structures involving Chinese biotech assets. In 2025, roughly 40% of all assets in-licensed by big pharma came from Chinese licensors, concentrated heavily in oncology ADCs and bispecifics. That channel is not closed, but it is more complicated. Fewer accessible targets means acquirers compete more aggressively for what is left, which compresses their return math at the same time the XBI’s move higher has already pushed target valuations up from the April 2025 lows. The pool is still deep. The average deal is just more expensive than it was.

What I keep coming back to is the timing problem markets have always had with M&A. The premium gets priced in at announcement. Not before. Institutional accumulation in likely targets starts well before any deal surfaces publicly, but the broader market assigns zero probability to an acquisition until the press release hits. That gap, between when smart positioning begins and when the announcement forces a rerating, is where the recurring opportunity lives in this cycle. And the XBI’s structure, all those small and mid-cap names at equal weight, is exactly the vehicle that captures it most efficiently when the deal activity is concentrated where it currently is.

The patent clock does not pause for macro uncertainty. The $1.3 trillion does not earn a return sitting in a balance sheet. What happens in the second half of 2026 will depend on how those two pressures interact, and which names find themselves in the path of both at the same time.

That is the part worth watching closely right now.